2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds

• US 20050043281A1
• Filed: 10/01/2004
• Published: 02/24/2005
• Est. Priority Date: 05/31/2000
• Status: Active Grant

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: DeLuca, Hector F., Sicinski, Rafal R.
• Granted Patent: US 6,992,074 B2
• Time in Patent Office: Days
• US Class Current: 514/167
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07C 401/00 : Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Abstract

Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone diseases where bone loss is a major concern. These compounds are also characterized by high cell differentiation activity.

Claims

1-56. -56. (Canceled)

57. A method of treating a metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound selected from the group consisting of

19-nor-2α

-ethyl-1α

,25-dihydroxyvitamin D₃,

19-nor-2β

-ethyl-1α

,25-dihydroxyvitamin D₃,

19-nor-20(S)-2α

-ethyl-1α

,25-dihydroxyvitamin D₃,

19-nor-20(S)-2β

-ethyl-1α

,25-dihydroxyvitamin D₃,

19-nor-2(E)-ethylidene-1α

,25-dihydroxyvitamin D₃,

19-nor-2(Z)-ethylidene-1α

,25-dihydroxyvitamin D₃,

19-nor-2(E)-ethylidene-20(S)-1α

,25-dihydroxyvitamin D₃,

19-nor-2(Z)-ethylidene-20(S)-1α

,25-dihydroxyvitamin D₃.

58. The method of claim 57 where the disease is senile osteoporosis.

59. The method of claim 57 where the disease is postmenopausal osteoporosis.

60. The method of claim 57 where the disease is steroid-induced osteoporosis.

61. The method of claim 57 where the disease is low bone turnover osteoporosis.

62. The method of claim 57 where the disease is osteomalacia.

63. The method of claim 57 where the disease is renal osteodystrophy.

64. The method of claim 57 wherein the compound is administered orally.

65. The method of claim 57 wherein the compound is administered parenterally.

66. The method of claim 57 wherein the compound is administered transdermally.

67. The method of claim 57 wherein the compound is administered in a dosage of from about 0.01 μ

g to about 50 μ

g per day.

68. The method of claim 57 wherein the compound is 19-nor-2α

-ethyl-1α

,25-dihydroxyvitamin D₃.

69. The method of claim 57 wherein the compound is 19-nor-2α

-ethyl-1α

,25-dihydroxyvitamin D₃.

70. The method of claim 57 wherein the compound is 19-nor-20(S)-2α

-ethyl-1α

,25-dihydroxyvitamin D₃.

71. The method of claim 57 wherein the compound is 19-nor-20(S)-20-ethyl-1α

,25-dihydroxyvitamin D₃.

72. The method of claim 57 wherein the compound is 19-nor-2(E)-ethylidene-1α

,25-dihydroxyvitamin D₃.

73. The method of claim 57 wherein the compound is 19-nor-2(Z)-ethylidene-1α

,25-dihydroxyvitamin D₃.

74. The method of claim 57 wherein the compound is 19-nor-2(E)-ethylidene-20(S)-1α

,25-dihydroxyvitamin D₃.

75. The method of claim 57 wherein the compound is 19-nor-2(Z)-ethylidene-20(S)-1α

,25-dihydroxyvitamin D₃.

76-116. -116. (Canceled)